Project Details
Description
A Phase 1/2 Study to Investigate the Safety, Tolerability and Potential Activity of IPI-504 in Relapsed ans/or Refractory Sage IIIb (with Malignant Pleural or Pericardial Effusion), or Stage IV NSCLC Patients
| Status | Finished |
|---|---|
| Effective start/end date | 2/2/10 → 4/8/10 |
Funding
- INFINITY PHARMACEUTICALS, INC
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.